Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
REN-M5222 | Mouse | Mouse RENIN Protein, His Tag |
|
||
REN-H5221 | Human | Human RENIN Protein, His Tag |
|
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Aliskiren Hemifumarate/Amlodipine Besilate/Hydrochlorothiazide | Approved | Novartis Pharma Ag | Rasitrio, Amturnide | United States | Hypertension | null | 2010-12-21 | Hypertension; Essential Hypertension | Details | |
Aliskiren Hemifumarate | SPP-100; SPP-100A; SPP-100B; CGP-60536; CGP-60536B | Approved | Novartis Pharma Ag | Enviage, Rasilez, Riprazo, Sprimeo, Tekturna, 锐思力 | United States | Hypertension | Noden Pharma Dac | 2007-03-05 | Myocardial Ischemia; Heart Failure; Diabetes Mellitus, Type 2; Glomerulonephritis, IGA; Myocardial Infarction; Coronary Artery Disease; Hypertension; Hypertrophy, Left Ventricular; Diabetic macular oedema; Cardiovascular Diseases; Essential Hypertension; Diabetic Nephropathies; Kidney Failure, Chronic; Diabetes Mellitus; Overweight | Details |
Aliskiren | Approved | Mainland China | Essential Hypertension | Novartis Pharma Ag | 2010-03-26 | Essential Hypertension | Details | |||
Aliskiren Hemifumarate/Amlodipine Besilate/Hydrochlorothiazide | Approved | Novartis Pharma Ag | Rasitrio, Amturnide | United States | Hypertension | null | 2010-12-21 | Hypertension; Essential Hypertension | Details | |
Aliskiren Hemifumarate | SPP-100; SPP-100A; SPP-100B; CGP-60536; CGP-60536B | Approved | Novartis Pharma Ag | Enviage, Rasilez, Riprazo, Sprimeo, Tekturna, 锐思力 | United States | Hypertension | Noden Pharma Dac | 2007-03-05 | Myocardial Ischemia; Heart Failure; Diabetes Mellitus, Type 2; Glomerulonephritis, IGA; Myocardial Infarction; Coronary Artery Disease; Hypertension; Hypertrophy, Left Ventricular; Diabetic macular oedema; Cardiovascular Diseases; Essential Hypertension; Diabetic Nephropathies; Kidney Failure, Chronic; Diabetes Mellitus; Overweight | Details |
Aliskiren | Approved | Mainland China | Essential Hypertension | Novartis Pharma Ag | 2010-03-26 | Essential Hypertension | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
MT-2765 | MT-2765 | Phase 3 Clinical | Mitsubishi Tanabe Pharma Corp | Hypertension | Details |
SP-20104 (Sarfez Pharmaceuticals) | SP-20104 | Phase 2 Clinical | 1 A Pharma Gmbh | Glomerulosclerosis, Focal Segmental | Details |
Imarikiren hydrochloride | TAK-272; SCO-272 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Kidney Diseases; Hypertension; Diabetic Nephropathies; Hepatic Insufficiency | Details |
MT-2765 | MT-2765 | Phase 3 Clinical | Mitsubishi Tanabe Pharma Corp | Hypertension | Details |
SP-20104 (Sarfez Pharmaceuticals) | SP-20104 | Phase 2 Clinical | 1 A Pharma Gmbh | Glomerulosclerosis, Focal Segmental | Details |
Imarikiren hydrochloride | TAK-272; SCO-272 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Kidney Diseases; Hypertension; Diabetic Nephropathies; Hepatic Insufficiency | Details |
This web search service is supported by Google Inc.